Background/aim: Major depressive disorder (MDD) is a significant cause of workforce loss, and is associated with cognitive impairments which can continue even after the elimination of mood and behavioural symptoms. The aim of this study was to investigate the benefit of transcranial magnetic stimulation (TMS) on cognitive functions in treatment resistant depression. Materials and methods: This randomised controlled clinical trial was conducted at a university hospital, department of psychiatry (tertiary centre) between October 2019 and July 2020. The study included 30 patients with depressive disorder, aged 18-50 years, who did not respond to at least two antidepressant medications for at least 8 weeks (one drug used was serotonin norepinephrine reuptake inhibitor [SNRI]; and 15 healthy control subjects. The patients were separated into two equal groups in a double-blind, random manner, and 20 sessions of repeated TMS was applied to one group, and 20 sessions of sham TMS to the other. The Montgomery Asberg Depression Scale (MADRS), Hamilton Depression Rating Scale (HAM-D), Stroop test, Wisconsin Card Sorting Test (WCST), Digit Span Test (DST), Trail Making Test A-B, and Verbal Memory Processes Test (VMPT) were applied to the patients before and after the TMS procedure. Results: The decrease in the HAM-D score was greater in the active magnetic stimulation (25 trains, 10 Hz, 110% motor threshold intensity) group, and with the exception of verbal memory processes, better performance was obtained by the active magnetic stimulation group than the sham group in the cognitive function tests. Conclusion: TMS was seen toimprove the cognitive defects present in the active phase of treatment-resistant depression, and therefore TMS could provide early improvement in cognitive functions in clinical use.
Purpose: It is known that there is a two-way relationship in the etiopathogenesis of depression and obesity. This study aimed to investigate serum ghrelin, leptin, neuropeptide Y levels, cognitive functions, and atypical depressive features in obese and depressed patients. It is expected that obese and depressed patients will show similar features in terms of biochemical parameters and cognitive functions, and atypical depressive features may be high in obese individuals. Materials and methods: The study included 56 obese individuals, 60 patients with major depressive disorder (MDD), and 53 healthy controls (HC). The questionnaires administered included socio-demographic data form, Hamilton Depression Rating Scale, Hamilton Anxiety Scale, Dutch Eating Behaviour Questionnaire, Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version (SIGH-SAD). Cognitive functions were assessed with short computer version of Wisconsin Card Sorting Test (WCST), Berg’s WCST, Stroop Colour-Word Test-Victoria version. Serum ghrelin, leptin, and neuropeptide Y levels were measured. Results: The depression scores were found higher MDD group than obesity and HC groups (p0.05). Differences were detected between the groups in the Stroop test. Leptin levels were higher (p<0.001), ghrelin (p=0.038) and neuropeptide Y (p<0.001) levels lower in obesity group compared to MDD and HC. Ghrelin levels negatively correlated with total number of incorrect responses in terms of cognitive functions in obese individuals (r=-0.259 p=0.049). Conclusion: In our study, it was determined that although depressive symptoms were high in obesity, there were no atypical depressive features, executive functions were similar between the groups, and neurochemical marker levels were not similar in obesity and depression. Our results do not support the relationship between obesity and atypical depression.
Kadriye Cansu Suguler, Osman Zulkif Topak, Osman Ozdel, Ibrahim Acikbas, Aysen Buket Er Urganci. Clin Psychopharmacol Neurosci 2025;23:356-67. https://doi.org/10.9758/cpn.24.1244
Purpose: Healthcare workers are exposed to long and stressful work shifts in pandemics. It was aimed to evaluate the coronavirus related anxiety levels of the healthcare workers, and to evaluate the relationship between their personality types and coping strategies. Materials and Methods: Study included 213 medical healthcare workers who were randomly selected and agreed to participate in the study on a voluntary basis. Sociodemographic data form, Coronavirus anxiety scale, Type A Behavior Test, and Coping styles scale was applied to the all participants. Results: The total coronavirus anxiety scores of the participants with type A personality traits were found to be significantly higher than with type B personality traits (p=0.006). The mean scores of helpless approach and seeking social support of were found to be significantly higher in participants with Type A personality (p=0.002, p=0.007, respectively). Self-confident and optimistic approach were found to be higher in participants with Type B personality (p=0.041, p=0.023, respectively). Participants with helpless approach had higher anxiety scores (p=0.033). A negative correlation was found between coronavirus anxiety and self-confident approach (p=0.002, r=-0.212) and optimistic approach (p=0.002, r=-0.209), and positive correlation with helpless approach (p=0.044, r=0.138). Conclusion: The results of this study showed that healthcare workers with type A personality use less self-confidence and optimistic approach, use more helpless approach, and have higher levels of dysfunctional coronavirus anxiety according to B type personality. Monitoring and ensuring the mental health of healthcare workers is crucial to global health in other possible pandemics.